Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells

Qiong Wu¹, Shu-Kui Qin²*, Feng-Meng Teng³, Chang-Jie Chen³, Rui Wang¹

Abstract

**Background:** Hepatocellular carcinoma (HCC) still is a big burden for China. In recent years, the third-generation platinum compounds have been proposed as potential active agents for HCC. However, more experimental and clinical data are warranted to support the proposal. In the present study, the effect of lobaplatin was assessed in five HCC cell lines and the underlying molecular mechanisms in terms of cell cycle kinetics were explored.

**Methods:** Cytotoxicity of lobaplatin to human HCC cell lines was examined using MTT cell proliferation assay. Cell cycle distribution was determined by flow cytometry. Expression of cell cycle-regulated genes was examined at both the mRNA (RT-PCR) and protein (Western blot) levels. The phosphorylation status of cyclin-dependent kinases (CDKs) and retinoblastoma (Rb) protein was also examined using Western blot analysis.

**Results:** Lobaplatin inhibited proliferation of human HCC cells in a dose-dependent manner. For the most sensitive SMMC-7721 cells, lobaplatin arrested cell cycle progression in G₁ and G₂/M phases time-dependently which might be associated with the down-regulation of cyclin B, CDK1, CDC25C, phosphorylated CDK1 (pCDK1), pCDK4, Rb, E2F, and pRb, and the up-regulation of p53, p21, and p27.

**Conclusion:** Cytotoxicity of lobaplatin in human HCC cells might be due to its ability to arrest cell cycle progression which would contribute to the potential use of lobaplatin for the management of HCC.

Background

Hepatocellular carcinoma (HCC) is one of the most common cancers with poor prognosis. In China alone, more than 401,000 new patients were diagnosed with HCC and more than 371,000 patients died of this disease in 2008 [1]. The poor outcome of HCC is mainly due to it rarely presents with characteristic symptoms at early stage and over 80% of patients lose the chance of curative hepatectomy when the diagnosis of HCC was confirmed [2].

For the management of advanced HCC, systemic chemotherapy with classical cytotoxic agents offers a marginal survival benefit [3,4]. To improve the chemotherapeutic efficacy, a few of novel cytotoxic agents have been employed to treat patients with HCC. Oxaliplatin, a third-generation platinum compound, has exhibited promising activity against advanced HCC with tolerable toxicity in phase II clinical trials [5,6]. Recently, a randomized controlled phase III trial has been performed to evaluate the efficacy of FOLFOX4 (oxaliplatin plus 5-fluorouracil/leucovorin) in Asian patients with advanced HCC. The data from first interim analysis have shown a significant advantage of FOLFOX4 over doxorubicin in terms of overall response rate (ORR), disease control rate (DCR), and time to progression (TTP) [7].

As another third-generation platinum compound, lobaplatin (D-19466; 1, 2-diammino-methyl-cyclobutaneplatinum(II)-lactate) has shown encouraging anti-cancer activity in a variety of tumor types without evident hepatotoxicity [8-10] and has been approved in China for the treatment of chronic myelogenous leukemia (CML), metastatic breast cancer and small cell lung cancer [11]. It is noteworthy that some tumors resistant to cisplatin are still sensitive to lobaplatin [8]. Base on these considerations, we speculate lobaplatin might be useful for advanced HCC patients but more experimental and clinical data are warranted. In the present study, the effect of lobaplatin was assessed in five human HCC cell lines and the underlying molecular mechanisms in terms of cell cycle kinetics were explored.
Materials and methods

Cell culture

Lobaplatin and oxaliplatin were purchased from Hainan Chang’an International Pharmaceutical (Hainan, China) and Sigma (St. Louis, MO, USA), respectively. The human HCC cell lines, SMMC-7721, Bel-7402, HepG2, and Huh-7, were obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). Hep 3B was kindly provided by Dr. X. Wang (Department of Oncology, Changzheng Hospital, Shanghai, China). All cell lines were maintained in Dulbecco’s modified Eagle’s medium (Gibco BRL, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco) at 37°C in a humidified atmosphere containing 5% CO2.

Proliferation assay

Cytotoxicity of lobaplatin to human HCC cell lines was examined using cell proliferation assay. Cells were seeded in a 96-well microtiter plate at 5 × 10^3 cells/well, and cultured for 24 hours prior to exposure to lobaplatin or oxaliplatin of varying concentrations for 48 hours. Ten μl 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT, 5 mg/ml) in phosphate buffered saline (PBS) were then added to each well. Four hours later the optical density (OD) was measured at 560 nm using a microplate reader (Thermo labsystems, Helsinki, Finland). All cell lines were maintained in Dulbecco’s modified Eagle’s medium (Gibco BRL, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco) at 37°C in a humidified atmosphere containing 5% CO2.

Flow cytometric (FCM) analysis

The effect of lobaplatin on human HCC cell cycle distribution was determined by FCM analysis. Cells were seeded in six-well plates at 5 × 10^5 cells/well and cultured for 24 hours prior to lobaplatin exposure for 0, 24, 36 and 48 hours. Control cells received only solvent for the indicated time durations above. Cells were collected by trypsinization, washed twice with ice cold PBS, fixed in 70% ethanol, and stained with propidium iodide (PI; 5 μg/ml PI in PBS containing 0.1% Triton X-100 and 0.2 mg/ml RNase A) overnight at 4°C in the dark until analyzed using a FACScan flow cytometer (BD Biosciences, San Jose, CA, USA). Cell fluorescence was measured in duplicate at each time point and all experiments were performed in triplicate.

Reverse transcription polymerase chain reaction (RT-PCR) analysis

The mRNA expression of cell cycle-regulated genes was examined by RT-PCR. Total RNA was extracted using Trizol solution (Invitrogen, Carlsbad, CA, USA). Single-stranded cDNAs were synthesized with oligo (dT) primers in a reaction starting with 2 μg of total RNA using SuperScript II reverse transcriptase (Fermentas Life Sciences, Hanover, MD, USA). PCR amplification was carried out in 25 μl total volume containing: 2 μl cDNA, 200 μM each dNTP, 0.25 units Taq polymerase, and 1 μM each primer (Sangon, Shanghai, China). Reaction conditions were optimized as follows: activation at 95°C for 5 min, followed by 30-35 cycles at 94°C for 45 s, 55-64°C for 45 s, and 72°C for 1 min. A series of calibration experiments verified that the conditions were within the exponential phase. The primers of cell cycle-regulated genes are listed in Table 1. The PCR product was analyzed by agarose gel electrophoresis and quantified using an image analyzer (Bio-Rad, Hercules, CA, USA). The result was verified in three independent experiments.

Western blot analysis

The protein expression of cell cycle-regulated genes was examined by Western blot. Cell extract was prepared using a non-denaturing lysis buffer. Protein concentration was determined using a Bio-Rad detergent-compatible protein assay kit (Bio-Rad). Samples (50-70 μg protein) were denatured in 5 × SDS-PAGE loading buffer and separated in 10% SDS-PAGE gels. The proteins were electro-transferred to nitrocellulose membranes followed by blocking with 5% (w/v) non-fat dry milk in Tris-buffered saline for 2 hours at room temperature. Membrane was probed with primary antibody at 1:400 dilution for 2 hours at room temperature and then washed three times with 0.1% Tween 20/PBS prior to incubation with an appropriate secondary antibody conjugated with peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1.5 hour. Signal detection was conducted using the enhanced chemiluminescence detection system (Bio-Rad). The blots shown are representative of three independent experiments. The primary antibodies to cyclin B, cyclin D1, CDK1, CDK4, CDK6, CDC25C, p53, p16, p21, p27, Rb, E2F, and GAPDH were purchased from Santa Cruz Biotechnology. To determine the levels of phosphorylated CDKs (pCDKs) and retinoblastoma (pRb) protein, the phospho-specific antibodies (Santa Cruz Biotechnology) targeting pCDK1 (Tyr15), pCDK4 (Tyr15), and pRb (Ser780) were used.

Results

Lobaplatin inhibited proliferation of human HCC cells

As shown in Figure 1A, lobaplatin inhibited cell proliferation of cultured human HCC cell lines with the IC50 values (48 h) ranging from 1.45 to 5.22 μg/ml. The rank order of sensitivity was p53 wild-type SMMC-7721 > Bel-7402 > p53 null Hep 3B > p53 mutant Huh-7.
The p53 wild-type HepG2 cell line showed a similar sensitivity to lobaplatin as the Huh-7 cells. In addition, lobaplatin appeared to have similar cytotoxicity profiles to oxaliplatin in these human HCC cell lines.

The dose-response curve of lobaplatin in SMMC-7721 cells was specially shown in Figure 1B. In a range of 0.25 to 4.5 μg/ml, lobaplatin inhibited cell proliferation of SMMC-7721 cells in a dose-dependent manner. The IC50 value of 1.45 μg/ml was chosen as a working concentration for subsequent cell cycle experiments in SMMC-7721 cells.

**Lobaplatin arrested cell cycle progression in G1 and G2/M phases time-dependently**

The effect of lobaplatin on cell cycle distribution of SMMC-7721 cells was shown in Figure 2. After adjustment with their corresponding controls, the proportions of G1, S, and G2/M phases in cells treated with lobaplatin were 45.31, 22.88, and 31.81% at 0 h, 59.91, 11.92, and 28.17% at 24 h, 56.89, 2.83, and 40.28% at 36 h, and 53.80, 2.07, and 44.13% at 48 h, respectively. Under the induction of lobaplatin, accumulation of cells in G1 phase occurred from 24 to 48 h and G2/M phase arrest appeared from 36 to 48 h. A concurrent reduction of

---

**Table 1 Primers for RT-PCR analysis**

| Gene    | Forward primer                        | Reverse primer                        |
|---------|---------------------------------------|---------------------------------------|
| cyclin B | GCACTTTCTCTCTCTCCTCAA                 | CTTGATGTTGGCCATCTC                   |
| cyclin D1 | CTGCGCTGAGAAGTTGGAACCAT               | TCAATGCCAGCGGGGAGACCT                |
| CDK1    | GATCTATCCCCTCTGTC                    | TAGGCTTCGTCGGTCC                    |
| CDK4    | CTGAGATGGTCTACCTCTGATATG             | AGAAGTAAACACAGCGGTTGAAG              |
| CDK6    | CGGATCTGATCGCGCCGATCTAA              | CTTTGCGGATCTGATAC                   |
| CDC25C  | GAACAGGCGCAAGCTGAGCC                 | GCCCGTGGGTAAGCTCC                    |
| p53     | GAGGCGCTGCCCAAGACCAGGGAAGC           | AGCCTCAGGACACATCCGAAAG              |
| p16     | AGCCTCAGGCGTGAACGGCTGG               | CGGCCATCATCATGACCTGG                |
| p21     | TAAGGCCTCCTCCTGAGAGGAGAT             | ATGTCGAGACCGGGGTGGGAGAT              |
| p27     | CCTCTCGGCCCGGTGGGAC                  | TTTGGGAAACCGTCTGAAAC                |
| GAPDH   | GGGAAAGGGAAGGTCCGGAGTC               | AGCAGAGGGGGCGAA                     |

---

**Figure 1** Lobaplatin inhibited proliferation of human HCC cells

(A) A comparison of lobaplatin and oxaliplatin in five human HCC cell lines. The IC50 value was determined using cell proliferation assay. (B) The dose-response curve of lobaplatin in SMMC-7721 cells. The cell proliferation rate of untreated cells was defined as 100% and that of treated cells was expressed as a percentage of the untreated cells. The data represented the mean ± standard deviations of three independent experiments.

**Figure 2** Lobaplatin arrested cell cycle progression in G1 and G2/M phases time-dependently. SMMC-7721 cells were treated with 1.45 μg/ml lobaplatin. In the course of treatment, cell cycle distribution was analyzed by FCM at 0, 24, 36, and 48 h. The profiles showed dual-variable plots of cell number versus PI uptake. G1, S, and G2/M cell populations were quantified.
the cell population in S phase was observed. These data suggested that lobaplatin could arrest cell cycle progression in G1 and G2/M phases time-dependently.

**Lobaplatin down-regulated cyclin B, CDK1, CDC25C, pCDK1, and pCDK4**

As shown in Figure 3A and Table 2, the mRNA levels of cyclin B, CDK1, and CDC25C phosphatase were moderately repressed at 24 h after lobaplatin treatment and significantly down-regulated at 36 and 48 h (changes > 2-fold). Meanwhile, the mRNA levels of cyclin D1, CDK4, and CDK6 were slightly enhanced or inhibited but the changes less than 2-fold compared to their controls. Lobaplatin did not appear to affect the mRNA levels of cyclin D1, CDK4, and CDK6.

The protein expression of genes mentioned above was generally consistent with the mRNA expression. As shown in Figure 3B and Table 3, the fold changes of genes at the mRNA level were further confirmed by the protein level.

Moreover, lobaplatin could regulate the phosphorylation status of CDKs and significantly reduce both pCDK1 after 24 h of treatment and pCDK4 after 36 h.

**Lobaplatin up-regulated p53, p21, and p27**

The effect of lobaplatin on p53 and CDK inhibitors (p16, p21, and p27) was subsequently examined at both the mRNA and protein levels (Figure 4, Table 2, 3). The results indicated that the expression of p53 was significantly increased within 24 h after lobaplatin treatment and p27 was up-regulated at somewhat later time points. The expression of p21 continued to be up-regulated and reached a peak of 7-fold increase at 36 h at the protein level. No significant change of p16 was found after lobaplatin treatment.

**Lobaplatin down-regulated Rb, E2F, and pRb**

During the lobaplatin treatment, the significant down-regulation of Rb appeared at 24 h followed by a persistent low level while its phosphorylation status (pRb) was significantly reduced in the late course of treatment. E2F also became significantly down-regulated after 36 h of lobaplatin treatment (Figure 5 and Table 3).

**Discussion**

The present study aimed at evaluating cytotoxicity of lobaplatin in human HCC cells in vitro. Among the five human HCC cell lines used, SMMC-7721 was the most sensitive one to lobaplatin and hence was selected as the cell model to reveal the underlying cytotoxic mechanisms of lobaplatin in terms of cell cycle kinetics. The results suggested that (i) lobaplatin could inhibit the proliferation of human HCC cells through arresting cell cycle progression in G1 and G2/M phases; (ii) The cell cycle arrest on human HCC cells induced by lobaplatin might be associated with the down-regulation of CDK1/cyclin B and Rb/E2F complexes and the up-regulation of CDK inhibitors.

Lobaplatin has shown favorable activity in various types of cancers including breast, oesophageal, lung, and ovarian cancers as well as CML [8]. In this study, lobaplatin exhibited evident cytotoxicity to human HCC cells. Interestingly, the p53 wild-type SMMC-7721 and Bel-7402 were the most sensitive cell lines to lobaplatin than Huh-7 which was p53 mutant. It indicates an important role for p53 phenotype in response to lobaplatin. However, the fact that p53 wild-type HepG2 cell line was resistant to lobaplatin suggests p53 phenotype is not the sole determinants of sensitivity to lobaplatin for human HCC cells. Moreover, characterized by p53 phenotype in these HCC cell lines, lobaplatin appeared to have similar cytotoxicity profiles to oxaliplatin which was active for advanced HCC patients [5,6]. The results indicate that lobaplatin may have potential value for the management of human HCC.
From the viewpoint of cell cycle, cytotoxicity of lobaplatin might be due to its ability to arrest cell cycle progression in our study. Upon incubation with lobaplatin, SMMC-7721 cells were continuously arrested in G1 phase after 24 h of treatment. It is well known that the complexes of CDK4, 6/cyclin D play an important role in G1-S transition by phosphorylating Rb [12,13]. As a consequence of Rb phosphorylation, E2F is released from the Rb/E2F complex, thereby activating the expression of the genes that are required for S phase transition [14]. Our results showed that the expression of CDK4, 6/cyclin D1 complexes was not affected by lobaplatin. Thus, there may be other mechanisms contributed to G1 phase arrest in this study. For the reason that the activity of CDKs is negatively controlled by binding CDK inhibitors to CDK/cyclin complexes [15], we examined the expression of CDK inhibitors both at the mRNA and protein levels. The results indicated that lobaplatin drastically enhanced the expression of p21 and p27, suggesting that CDKs activity may be inhibited by these two CDK inhibitors. Furthermore, lobaplatin down-regulated the expression of Rb/E2F complex and consequently inhibited the expression of E2F target genes. Meanwhile, the changes of pCDK4 and pRb were revealed in accordance with this cell cycle variation.

The cell cycle analysis in this study revealed a prominent G2/M phase arrest in the late course of lobaplatin treatment. G2/M transition is partly governed by the activity of CDK1, which is positively regulated by cyclin B [16]. CDK1 activation is also controlled by dephosphorylation at Tyr15 by CDC25C phosphatase [16,17]. Lobaplatin significantly down-regulated cyclin B, CDK1, and CDC25C as well as pCDK1. Absence of cyclin B and CDK1 after 36 h of treatment might have contributed to G2/M phase arrest as a late event. The reduced expression of CDC25C may have contributed to the lower CDK1 activity.

As an essential cell cycle regulator, the p53 tumor suppressor plays an important role in the cellular response to platinum agents. For example, 1,2-diaminocyclohexane-acetato-Pt could arrest the wild-type p53 cells in G1 phase and the mutant p53 cells in G2/M phase in ovarian cancer [18]. P53 transcriptionally activates a series of genes involved in both G1-S and G2-M transitions in response to genotoxic stress [19,20]. Among these genes, p21 is a well-established negative regulator of G1-S transition [19]. It also inhibits the CDK1/cyclin B complex and keeps G2 arrest maintenance [20]. In the present study, lobaplatin induced a rapid accumulation of p53 which occurred within 24 h of lobaplatin treatment. Consistent with this finding, p21 was strongly up-regulated with a 7-fold increase at 36 h after lobaplatin treatment. The data suggest that the p53-p21 pathway may contribute to G1 and G2/M cell cycle arrests in this p53 wild-type SMMC-7721 cells [21,22].

Being similar to cisplatin, lobaplatin induces intra-strand DNA-Pt crosslinks [23] but somewhat less efficiently [24]. Lobaplatin shows incomplete cross-resistance with cisplatin [23] which suggest the former might have an underlying action mechanism different from the latter. Cisplatin can reduce the DNA synthesis rate with a subsequent accumulation in S phase followed by G2/M phase arrest [25-27]. The results in our study lobaplatin arrested SMMC-7721 cells in G1 and G2/M phases demonstrate the existence of a different action mechanism of lobaplatin. Oxaliplatin, another third-generation platinum compound, could activate G1-S checkpoint and block G2-M transition completely in p53 wild-type HCT-116 colon

| Treatment time | cyclin B | cyclin D1 | CDK1 | CDK4 | CDK6 | CDC25C | p53 | p16 | p21 | p27 |
|----------------|----------|-----------|------|------|------|--------|-----|-----|-----|-----|
| 0 h            | 1        | 1         | 1    | 1    | 1    | 1      | 1   | 1   | 1   | 1   |
| 12 h           | 0.89     | 1.47      | 0.83 | 1.21 | 1.10 | 0.51   | 3.03| 1.22| 2.05| 1.26|
| 24 h           | 0.53     | 1.36      | 0.53 | 0.95 | 1.14 | 0.54   | 2.69| 1.85| 2.50| 1.32|
| 36 h           | 0.18     | 0.87      | 0.25 | 0.52 | 1.18 | 0.21   | 1.30| 1.59| 3.14| 2.05|
| 48 h           | 0.09     | 0.59      | 0.13 | 0.53 | 1.04 | 0.12   | 0.79| 1.77| 3.64| 1.95|

Table 2 Genes/GAPDH ratio at the mRNA level (The densitometric data are presented as fold changes as compared with their corresponding controls)

| Treatment time | cyclin B | cyclin D1 | CDK1 | pCDK1 | CDK4 | pCDK4 | CDK6 | pCDK4 | pCDK4 | CDC25C | p53 | p16 | p21 | p27 | E2F | Rb | pRb |
|----------------|----------|-----------|------|-------|------|-------|------|-------|-------|--------|-----|-----|-----|-----|-----|-----|-----|
| 0 h            | 1        | 1         | 1    | 1     | 1    | 1     | 1    | 1     | 1     | 1      | 1   | 1   | 1   | 1   | 1   | 1   | 1   |
| 12 h           | 0.94     | 1.17      | 0.79 | 1.50  | 1.15 | 0.75  | 1.21 | 1.25  | 4.16  | 0.87   | 2.15| 1.58| 1.14| 0.98| 1.01|
| 24 h           | 0.47     | 1.28      | 0.59 | 0.39  | 0.95 | 0.51  | 1.04 | 1.58  | 2.41  | 1.66   | 5.32| 2.04| 0.81| 0.39| 0.55|
| 36 h           | 0.26     | 0.77      | 0.23 | 0.15  | 0.56 | 0.36  | 1.11 | 0.63  | 1.57  | 1.39   | 7.00| 3.00| 0.46| 0.45| 0.29|
| 48 h           | 0.07     | 0.64      | 0.09 | 0.02  | 0.65 | 0.19  | 1.19 | 0.47  | 0.63  | 1.74   | 5.63| 1.96| 0.40| 0.39| 0.34|
In vitro encouraging efficacy of lobaplatin against human HCC with its incomplete cross-resistance with cisplatin. Management of HCC.

Further studies should be conducted to examine whether the effect of lobaplatin on G1-S transition is associated with its incomplete cross-resistance with cisplatin.

In conclusion, the present study demonstrated the encouraging efficacy of lobaplatin against human HCC in vitro. Lobaplatin could arrest cell cycle in G1 and G2/M phases which was possibly associated with the down-regulation of cyclin B, CDK1, CDC25C, pCDK1, pCDK4, Rb, E2F, and pRb, and up-regulation of p53, p21, and p27. These alterations of cell cycle kinetics might contribute to a better understanding for cytotoxicity of lobaplatin and facilitate its potential use for the management of HCC.

Figure 4 Lobaplatin up-regulated p53, p21, and p27. Expression of p53 and CDK inhibitors was determined at 0, 12, 24, 36, and 48 h in SMMC-7721 cells after 1.45 μg/ml lobaplatin treatment. GAPDH as a control. (A) The mRNA level. (B) The protein level.

Figure 5 Lobaplatin down-regulated Rb, E2F, and pRb. The protein expression of Rb, E2F and pRb was examined at 0, 12, 24, 36, and 48 h in SMMC-7721 cells after 1.45 μg/ml lobaplatin treatment. GAPDH as a control.

Acknowledgements
This study was supported by the National High Technology Research and Development Program of China (863 Program, No.2006AA020608). We thank Hui Wang for excellent technical assistance in cell culture.

Author details
1Department of Medical Oncology, Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China. 2Department of Oncology, the 81 Hospital of the Chinese People’s Liberation Army, Nanjing, China. 3Department of Laboratory Medicine, Bengbu Medical College, Bengbu, Anhui, China.

Authors’ contributions
QW and SKQ were responsible for research design and manuscript preparing. FMT, CJC, and RW performed the experiments and analyzed the data. All authors have read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 27 July 2010 Accepted: 31 October 2010
Published: 31 October 2010

References
1. Fletay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer 2010 [http://globocan.iarc.fr].
2. Hung H: Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets 2005, 5:131-138.
3. Buij J, Sherman M, Libvet JM, Beaugrand M, Lencione R, Buncoughs AK, Christensen E, Pagliaro L, ColoMbo M, Rodés J, EASL, Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
4. Thomas MB, O’Beirne JP, Puruse J, Chan AT, Abou-AIa G, Johnson P: Systemtic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 2008, 15:1008-1014.
5. Louafi S, Boise V, Ducrueux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannonn L, Paynard T, Taieb J: Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007, 109:1384-1390.
6. Boise V, Raoul JL, Pignon JP, Bouché O, Blanc JF, Dahan L, Jouve JL, Dupoux N, Ducrueux M, Fédération Francophone de Cancérologie Digestive Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007, 97:862-867.
7. Qin S, Bai Y, Ye S, Fan J, Lim H, Cho JY, Thongprasert S, Chao Y, Rau K, Sun Y: Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients [meeting abstract]. J Clin Oncol 2010, 28:4008.
8. Mchicage MJ: Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs 2001, 10:119-128.
9. Getema JA, de Vries EG, Sealfier DT, Willemsse PH, Guchelaar HJ, Uges DR, Aulenbacher P, Voegeli R, Mulder NH: A phase I study of 1,2-diaminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br J Cancer 1993, 67:396-401.
10. Fiebig HH, Hens H, Mios K: Phase I clinical trial of lobaplatin (D-19466; lobaplatin) after intravenous bolus injection. Onkologie 1994, 17:142-148.
11. State Food and Drug Administration Database. [http://appt.ffd.gov.cn/ datasearch/face3/faxie.jsp].
12. Deshpande A, Scinski P, Hinds PW: Cyclins and cdks in development and cancer: a perspective. Oncogene 2005, 24:2909-2915.
13. Coqueret O: Linking cyclins to transcriptional control. Gene 2002, 293:35-55.
14. Harbour JW, Dean DC: The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000, 14:2393-2409.
15. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995, 9:1149-1163.
16. O’Connor PM. Mammalian G1 and G2 phase checkpoints. Cancer Surv 1997, 29:151-182.
17. Nurse P. Universal control mechanism regulating onset of M-phase. Nature 1990, 344:503-508.
18. Hagopian GS, Mills GB, Khokhar AR, Bast RC Jr, Siddik ZH. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum (IV). Clin Cancer Res 1999, 5:655-663.
19. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-1512.
20. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815.
21. Gong L, Jin X, Li Q, Liu J, An L. Heavy ion beams induce survivin expression in human hepatoma SMMC-7721 cells more effectively than X-rays. Acta Biochim Biophys Sin (Shanghai) 2007, 39:575-582.
22. Fan H, Zhao ZJ, Cheng YC, Shan YF, Lu ZH, Zhang QJ, Xie W. Gene induction and apoptosis in human hepatocellular carcinoma cells SMMC-7721 exposed to 5-aza-2’-deoxycytidine. Chin Med J (Engl) 2007, 120:1626-1631.
23. Harstrick A, Bokemeyer C, Schamofkse M, Hapke G, Reile D, Schmoll HJ. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. Cancer Chemother Pharmacol 1993, 33:43-47.
24. Saris CP, van de Vaart PJ, Rietbroek RC, Blommaert FA. In vitro formation of DNA adducts by cisplatin, lobaplatin, and oxaliplatin in human DNA in solution and in cultured human cells. Carcinogenesis 1996, 17:2763-2769.
25. Sorenson CM, Eastman A. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 1988, 48:6703-6707.
26. Ormerod MG, Orr RM, Peacock JH. The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br J Cancer 1994, 69:93-100.
27. Nishio K, Fujiwara Y, Miyahara Y, Takeda Y, Ohita T, Kubota N, Ohto S, Funayama Y, Ogasawara H, Ohta M. cis-Diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung-cancer cells. Int J Cancer 1993, 55:616-622.
28. Voland C, Bord A, Péleraux A, Pénarier G, Camère D, Galiègue S, Cvitkovic E, Jbilò O, Casellas P. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther 2006, 5:2149-2157.

doi:10.1186/1756-8722-3-43
Cite this article as: Wu et al. Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells. Journal of Hematology & Oncology 2010, 3:43.